drugset / Trial / NCT04222790

A Study of Monosialic Gangliosides to Prevent Albumin-bound Paclitaxel Neurotoxicity

NCT04222790 ↗

Phase 2 Completed 159 enrolled Henan Cancer Hospital
RandomizedParallel-groupDouble-blindTreatment

Summary

Taxane-induced peripheral neuropathy (TIPN) caused by paclitaxel is a dose-limiting toxicity. The main symptoms of discomfort are numbness, tingling, and burning sensations in the glove-sock-like distribution of the limbs. At present, there are few effective methods for clinical treatment of TIPN, and there is no widely agreed consensus on effective treatment in the world. Therefore, it is of great clinical significance and practical value to carry out clinical research to explore drugs to relieve TIPN.

Timeline

Start
2020-08-28
Primary completion
2022-04-21
Completion
2022-04-21

Drugs

EvaluationDrugModalityDoseRoute
Subject monosialic gangliosides Unknown 80 mg —